Generic drugmaker Dr. Reddy’s Laboratories’ consolidated net profit for the June quarter increased marginally to ₹1,409.9 crore from Rs.1,392.4 crore year earlier as revenue from the all important U.S. market declined amid increased price erosion in certain key products. The net profit came on a more than 11% increase in total revenue from operations to […]
Continue Reading
Representational image only. | Photo Credit: Special Arrangement Pharma major Dr. Reddy’s Laboratories is acquiring the U.S. generic prescription product portfolio of Australia’s Mayne Pharma Group for an upfront cash consideration of around $90 million. The portfolio includes 45 commercial products, four pipeline products and 40 approved non-marketed products, including generic products focussed on women’s […]
Continue Reading
As part of the settlement, the underlying litigation will be dismissed, the Hyderabad-headquartered drugmaker said. As part of the settlement, the underlying litigation will be dismissed, the Hyderabad-headquartered drugmaker said. Pharma major Dr. Reddy’s Laboratories has entered into settlement agreement with British drugmaker Indivior resolving patent litigation relating to latter’s opioid dependence treatment drug Suboxone. […]
Continue ReadingCopyright © 2022
Designed and Developed by Cpool Digital Learning
